Article
Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity.
The Biochemical journal - 1 Sept 2008
Paproski Robert J, Visser Frank, Zhang Jing, Tackaberry Tracey, Damaraju Vijaya, Baldwin Stephen A, Young James D, Cass Carol E
Abstract excerpt
hENT1 (human equilibrative nucleoside transporter 1) is inhibited by nanomolar concentrations of various structurally distinct coronary vasodilator drugs, including dipyridamole, dilazep, draflazine, soluflazine and NBMPR (nitrobenzylmercaptopurine ribonucleoside). When a library of randomly mutated hENT1 cDNAs was screened using a yeast-based functional complementation assay for resistance to dilazep, a clone...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
